Poseida is a clinical-stage biopharmaceutical company building out a wholly-owned pipeline of Chimeric antigen receptor T cell (CAR-T) product candidates, initially focused on the treatment of haematologoical malignancies, like multiple myeloma, and solid tumours, like prostate cancer.

In January 2025, Poseida was acquired by Roche at a price of $9.00 per share in cash at closing, plus contingent value rights (“CVRs”) to receive certain contingent payments of up to $4.00 per share in cash upon achievement of specific future milestones. This resulted in the payment of upfront proceeds of €103.4 million to Malin in January 2025. Through its interest in the CVRs, Malin has the potential to receive up to a further $47.3 million conditional upon the achievement of the following milestones before the specified expiry dates:

i. US $2.00 per share in cash, upon the initiation of the first pivotal study of a P-BCMA-ALLO1 product for the treatment of any indication (expiring 31 December 2028);

ii. US $1.00 per share in cash, upon the initiation of the first pivotal study of a P-CD19CD20-ALLO1 product or of a P-BCMACD19-ALLO1 product for the treatment of an autoimmune indication (expiring 31 December 2034); and

iii. US $1.00 per share in cash, upon the first commercial sale of a P-BCMA ALLO1 product for the treatment of any indication (expiring 31 December 2031).

> go to website

Viamet represents a financial interest for Malin in VIVJOA™, an FDA-approved medication for the treatment of recurrent vulvovaginal candidiasis (RVVC), an unmet need in women’s health, and in a Phase 3 compound for the treatment of onychomycosis, fungal nail infection.

In April 2022, Mycovia (Viamet’s successor company) announced the approval from the US FDA of VIVJOA™ for the treatment of RVVC in females with a history of RVVC and who are not of reproductive potential.

> go to website

Xenex is a commercial-stage medical device company focused on reducing healthcare-associated infections with its unique non-mercury, full-spectrum disinfection LightStrike^TM Germ-Zapping^TM robots. Xenex aims to become the new standard of care for disinfection in healthcare facilities worldwide, eliminating harmful bacteria, viruses and fungi which can cause healthcare associated infections in patients and staff.

> go to website

KNOW Bio is a privately held life science company utilising its extensive catalogue of intellectual property in the fields of nitric oxide and precision light therapy to develop unique treatments to revolutionise the standard of care for many indications.

> go to website

Artizan is an early-stage biotechnology company focused on developing a platform to eliminate disease-causing bacteria in the gut microbiota. Artizan's initial focus is on inflammatory bowel disease, specifically Crohn's Disease and Ulcerative Colitis.

> go to website